BCL2 and esophageal cancer: The results showed that 23-HBA downregulated Bcl-2 and upregulated Caspase-3 protein expression.<h4>Conclusion</h4>23-HBA inhibits mitosis in esophageal cancer by blocking the BUB1/STAT3 signaling pathway, suggesting its potential as a therapeutic agent for esophageal cancer treatment.